10th week of 2016 patent applcation highlights part 21 |
Patent application number | Title | Published |
20160068503 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME - A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula: | 2016-03-10 |
20160068504 | CYCLIC ORTHO ESTER FUEL ADDITIVE - The invention relates to liquid hydrocarbons containing cyclic ortho esters as dehydrating dehydrating icing inhibitors and to methods of using the compounds. The liquid hydrocarbons include fuels such aviation fuels, lubricants, hydraulic fluids and hydrocarbon solvents. | 2016-03-10 |
20160068505 | Process for Recovering and Improving Production of Meso-Lactide from a Crude Lactide Containing Stream - A process for the recovery and production of meso-lactide from a crude lactide containing stream may include subjecting a starting crude lactide stream to a first distillation step to obtain: a top stream mainly containing meso-lactide; a bottom stream; and a side stream mainly containing L-lactide and meso-lactide. The process may include recovering the side stream and subjecting the side stream to a melt crystallization step to obtain: a first purified stream mainly containing L-lactide; and a drain stream mainly containing meso-lactide and L-lactide. The process may include recovering the top stream and drain stream, and subjecting the top stream and drain stream to a second distillation step to obtain a second purified stream containing L-lactide and meso-lactide. | 2016-03-10 |
20160068506 | COMBRETASTATIN ANALOGS - The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided. | 2016-03-10 |
20160068507 | HISTONE DEMETHYLASE INHIBITORS - Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. | 2016-03-10 |
20160068508 | Muscarinic M1 Receptor Agonists - This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R | 2016-03-10 |
20160068509 | PYRIDAZINONES AS HERBICIDES - Disclosed are compounds of Formula 1, including all stereoisomers, (N-oxides), and salts thereof, | 2016-03-10 |
20160068510 | HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS - The present invention is directed to hydroxy compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2016-03-10 |
20160068511 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF - The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family. | 2016-03-10 |
20160068512 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists - The present invention is directed to quinazoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders. | 2016-03-10 |
20160068513 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF - Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer. | 2016-03-10 |
20160068514 | HALO AND TRIFLUOROMETHYL SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS - The present invention is directed to halo and trifluoromethyl substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2016-03-10 |
20160068515 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Provided is a triazolone derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The triazolone derivative or its pharmaceutically acceptable salt can effectively activate GPR119; and therefore be usefully applied for preventing or treating diabetes mellitus. | 2016-03-10 |
20160068516 | NOVEL TRIAZOLE DERIVATIVES - The present invention relates to novel triazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators. | 2016-03-10 |
20160068517 | 5-BROMO-INDIRUBINS - Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives. | 2016-03-10 |
20160068518 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS - The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection. | 2016-03-10 |
20160068519 | INHIBITORS OF THE ENZYME UDP-GLUCOSE: N-ACYL-SPHINGOSINE GLUCOSYLTRANSFERASE - This invention relates to novel inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase. | 2016-03-10 |
20160068520 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula | 2016-03-10 |
20160068521 | THIAZOLES AND USES THEREOF - This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 2016-03-10 |
20160068522 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE - The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders. | 2016-03-10 |
20160068523 | Benzene Sulfonamide Thiazole and Oxazole Compounds - The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents. | 2016-03-10 |
20160068524 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE - The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders. | 2016-03-10 |
20160068525 | Fused Heterocyclic Compounds as Selective BMP Inhibitors - The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. | 2016-03-10 |
20160068526 | BENZOQUINOLONE INHIBITORS OF VMAT2 - The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. | 2016-03-10 |
20160068527 | The Treatment of Inflammatory Disorders - The present invention provides Nalidixic acid and analogues of Nalidixic acid, and methods for treating inflammatory disorders. The Nalidixic acid and analogues of Nalidixic acid may be formulated for topical delivery or systemic delivery. The inflammatory disorders that may be treated with the Nalidixic acid and analogues of Nalidixic acid include respiratory diseases, chronic degenerative diseases, dematological conditions, chronic demyelinating diseases, dental diseases, ophthalmic conditions, inflammatory bowel diseases, and graft versus host diseases. | 2016-03-10 |
20160068528 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses. | 2016-03-10 |
20160068529 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2016-03-10 |
20160068530 | SOLID STATE FORMS OF VEMURAFENIB AND VEMURAFENIB SALTS - The present invention provides Vemurafenib salts, particularly Vemurafenib esylate and Vemurafenib choline, and solid state forms thereof and processes for preparing these compounds. The present invention also provides the use of the solid state forms of Vemurafenib and of the Vemurafenib salts for preparing Vemurafenib or other Vemurafenib salts, and solid state forms thereof. | 2016-03-10 |
20160068531 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION - The invention provides novel compounds having the general formula: | 2016-03-10 |
20160068532 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS - Disclosed are the ERK inhibitors of formula (I) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I). This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier. This invention also provides a method of inhibiting ERK (i.e., inhibiting the activity of ERK2) in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of formula (I). | 2016-03-10 |
20160068533 | IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES - The invention provides compounds of formula I: | 2016-03-10 |
20160068534 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE - The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4 | 2016-03-10 |
20160068535 | PYRROLOTRIAZINES AS ALK INHIBITORS - This application provides compounds of the general formula (I) | 2016-03-10 |
20160068536 | Antimicrobial Monomers and Polymers, and Their Use in Dental Devices - Antimicrobial compounds are provided that are polymerizable. The compounds include monomers with antimicrobial properties. The compounds have cross-linking properties and are hydrolytically stable. The compounds may be utilized in dental and/or medical applications, including dental composites, dentures, bonding agents, sealants, resins and medical devices. | 2016-03-10 |
20160068537 | COMPOUNDS FOR TREATMENT OF PAIN - The invention is directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient. | 2016-03-10 |
20160068538 | PROCESS FOR PREPARING 7BETA-SUBSTITUTED 6ALPHA,14ALPHA-ETHENOMORPHINANS AND 7BETA-SUBSTITUTED 6ALPHA,14ALPHA-ETHANOMORPHINANS - The application is directed to a process for increasing the proportion of 7β-epimer in an 7α/7β-epimer mixture of a 7-substituted 6α,14α-ethenomorphinan or a 7-substituted 6α,14α-ethanomorphinan, and specifically of compounds of Formula (I), wherein G, R | 2016-03-10 |
20160068539 | PROTEASE INHIBITORS - Compounds of the formula II: | 2016-03-10 |
20160068540 | CRYSTAL FORMS OF (R)-N-METHYLNALTREXONE BROMIDE AND USES THEREOF - The present invention provides a new forms of (R)—N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist. | 2016-03-10 |
20160068541 | ANALGESIC COMPOUNDS AND METHODS OF USE - Provided herein, inter alia, are methods and compositions for achieving an analgesic effect in subjects in need thereof. | 2016-03-10 |
20160068542 | Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells - Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells. | 2016-03-10 |
20160068543 | IRAK INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2016-03-10 |
20160068544 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (Ia): | 2016-03-10 |
20160068545 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN - Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, | 2016-03-10 |
20160068546 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES - A compound of Formula I | 2016-03-10 |
20160068547 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2016-03-10 |
20160068548 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2016-03-10 |
20160068549 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2016-03-10 |
20160068550 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2016-03-10 |
20160068551 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2016-03-10 |
20160068552 | VINBLASTINE DERIVATIVES, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - The present invention provides a new kind of vinca alkaloid derivatives, new applications thereof and preparation methods therefor. The vinca alkaloid derivatives comprise hydrazinolyzed vinca alkaloids and vinca alkaloid dipeptide derivative. The hydrazinolyzed vinca alkaloids are the compounds obtained from the reaction of vinca alkaloids or salts thereof with hydrazinolyzed hydrate; and the vinca alkaloid dipeptide derivatives are the compounds obtained from the condensation of hydrazinolyzed vinca alkaloids with N-benzyloxycarbonylglycyl proline. The present invention provides the uses of the vinca alkaloids derivatives or the pharmaceutical compositions thereof in anti-tumor, preventing or treating diabetic retinopathy, rheumatoid arthritis and serving as angiogenesis inhibitors or vascular disrupting agents. | 2016-03-10 |
20160068553 | NOVEL COMPOUND AND RESIN COMPOSITION CONTAINING THE SAME - To provide a compound which can demonstrate flame retardancy equal to or higher than V-1 of the UL94 standard by adding a flame retardant to resin containing aromatic polyester and styrene polymer. | 2016-03-10 |
20160068554 | SURFACE-TREATED CALCIUM PHOSPHATE PARTICLES SUITABLE FOR ORAL CARE AND DENTAL COMPOSITIONS - Calcium phosphate particles are described comprising a surface treatment wherein the surface treatment comprises at least one sugar alcohol. Also described are various oral care compositions comprising surface treated calcium phosphate particles and methods of surface treating calcium phosphate particles. | 2016-03-10 |
20160068555 | METAL UTILIZATION IN SUPPORTED, METAL-CONTAINING CATALYSTS - Generally, the present invention relates to improvements in metal utilization in supported, metal-containing catalysts. For example, the present invention relates to methods for directing and/or controlling metal deposition onto surfaces of porous substrates. The present invention also relates to methods for preparing catalysts in which a first metal is deposited onto a support (e.g., a porous carbon support) to provide one or more regions of a first metal at the surface of the support, and a second metal is deposited at the surface of the one or more regions of the first metal. Generally, the electropositivity of the first metal (e.g., copper or iron) is greater than the electropositivity of the second metal (e.g., a noble metal such as platinum) and the second metal is deposited at the surface of the one or more regions of the first metal by displacement of the first metal. The present invention further relates to treated substrates, catalyst precursor structures and catalysts prepared by these methods. The invention further relates to use of catalysts prepared as detailed herein in catalytic oxidation reactions, such as oxidation of a substrate selected from the group consisting of N-(phosphonomethyl)iminodiacetic acid or a salt thereof, formaldehyde, and/or formic acid. | 2016-03-10 |
20160068556 | TARGETED NITROXIDE AGENTS - A compound having a structure of: | 2016-03-10 |
20160068557 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF - The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof. | 2016-03-10 |
20160068558 | ANTICANCER AGENTS OF THE ANTHRACYCLIN FAMILY - Anthracyclin compounds of the general structure: | 2016-03-10 |
20160068559 | Modulators of Histone Methyltransferase, and Methods of Use Thereof - Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity. | 2016-03-10 |
20160068560 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING - The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS. | 2016-03-10 |
20160068561 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same - A compound represented by the general formula (III) which serves as an intermediate of an oligonucleotide analog having stable and excellent antisense or antigene activity or having excellent activity as a detection reagent (probe) for a specific gene or as a primer for the initiation of amplification of a specific gene can be produced at high yields regardless of the type of nucleobase by a method comprising reacting a compound represented by the general formula (II) or a salt thereof with a trimethylsilylated compound obtained from a compound represented by the general formula (IVb), wherein X, Y, Z, A, R, and B are as defined in claim | 2016-03-10 |
20160068562 | Raman Tag - The present invention provides novel Raman tags for exploring membrane interactions in cells. The tags comprise a phenyl diyne probe where in the dyine is capped with the phenyl group. Methods for using the tags are also provided. | 2016-03-10 |
20160068563 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF - Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus. | 2016-03-10 |
20160068564 | METHOD FOR ISOLATING CASPOFUNGIN - The present invention relates to a method for isolating caspofungin and to a novel crystalline form of caspofungin diacetate thus obtained. | 2016-03-10 |
20160068565 | METHOD FOR HARVESTING CULTURE PRODUCT - The present invention provides a more productive method for culturing and a more productive method for harvesting culture product in cell culture wherein the cell produces the culture product. The present invention relates to a method for harvesting a culture product contained in a culture solution in the cell culture wherein the cell produces the culture product, comprising the following steps: B sending the culture solution to a filtration membrane; C: filtering the culture solution by alternating tangential flow filtration while changing the flow of the culture solution so as to cause a reciprocating motion thereof in a direction parallel with the surface of the filtration membrane to obtain a filtrate; D: sending back a culture solution residue that has remained without permeating the filtration membrane; and G: harvesting the culture product from the filtrate, wherein
| 2016-03-10 |
20160068566 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS - The present invention concerns a compound of following formula (I): where: —R | 2016-03-10 |
20160068567 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS - The present invention concerns a compound of following formula (I) where: —R | 2016-03-10 |
20160068568 | MODULATORS OF THE SRC-KINASE ACTIVITY FOR PREVENTING OR TREATING METASTATIC CANCER - The invention provides a molecule that modulates an activity of a Src family kinase for use in preventing or treating a metastatic cancer a subject. Preferably, the molecule comprises or consists of the structure: B | 2016-03-10 |
20160068569 | STRUCTURE-BASED PEPTIDE INHIBITORS OF P53 AGGREGATION AS A NEW APPROACH TO CANCER THERAPEUTICS - This invention relates, e.g., to an inhibitory peptide or CPP inhibitor which specifically binds to p53 having an aberrant conformation (e.g., is aggregated or misfolded) and inhibits p53 amyloidogenic aggregation or restores proper folding of the misfolded protein. Methods of using the inhibitory peptide or CPP inhibitor (e.g. to treat subjects having tumors that comprise aggregated p53) are described. | 2016-03-10 |
20160068570 | ANTI-TUMOR POLYPEPTIDES AND METHOD FOR PREPARING ANTI-TUMOR DRUGS COMPRISNG THE SAME - An anti-tumor polypeptide, having an amino acid sequence represented by FPGSDRF (SEQ ID NO. 15), X-FPGSDRF, FPGSDRF-Z, or X-FPGSDRF-Z, in which the various capital letters denote amino acids: F: phenylalanine; P: proline; G: glycine; S: serine; D: aspartic acid; R: arginine; S is a phosphorylated serine residue, X and Z are an amino acid residue or an amino acid sequence, respectively, X is one selected from the group consisting of F, (R) | 2016-03-10 |
20160068571 | THERAPEUTIC AGENT FOR CARDIAC TAMPONADE | 2016-03-10 |
20160068572 | NEW STABLE PENTADECAPEPTIDE SALTS, A PROCESS FOR PREPARATION THEREOF, A USE THEREOF IN THE MANUFACTURE OF PHARMACEUTICAL PREPARATIONS AND A USE THEREOF IN THERAPY - The present invention discloses new stable pentadecapeptide salts of formula (I): | 2016-03-10 |
20160068573 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease. | 2016-03-10 |
20160068574 | Modified Proteins and Methods of Use Thereof - This invention is generally related to small proteins, such as miniature proteins, including avian pancreatic polypeptide (aPP), modified so that the small proteins reach the cytosol. In some embodiments, the modified protein molecules deliver an associated cargo molecule to the cytosol. Other embodiments of the invention relate to modified protein fusion molecules that reach the cytosol. | 2016-03-10 |
20160068575 | NOVEL RECOMBINANT BACULOVIRUS VECTOR AND USES THEREOF - Disclosed herein is a recombinant viral construct and its uses thereof. The recombinant viral construct is capable of simultaneously expressing three exogenous proteins, including a classical swine fever virus (CSFV) antigen, a porcine | 2016-03-10 |
20160068576 | Vault Complexes for Facilitating Biomolecule Delivery - The invention relates to compositions of vault complexes containing recombinant membrane lytic proteins, such as an adenovirus protein VI lytic domain, and methods of using the vault complexes to facilitate delivery and entry of a biomolecule into a cell or subject. | 2016-03-10 |
20160068577 | CYTOTOXIC PROTEINS COMPRISING CELL-TARGETING BINDING REGIONS AND SHIGA TOXIN A SUBUNIT REGIONS FOR SELECTIVE KILLING OF SPECIFIC CELL TYPES - The present invention provides cytotoxic proteins comprising immunoglobulin-type binding regions for mediating cell-type specific targeting and Shiga toxin effector regions derived from A Subunits of members of the Shiga toxin family for effectuating cytotoxicity. The cytotoxic proteins have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. | 2016-03-10 |
20160068578 | COMPOSITIONS AND METHODS RELATED TO PROTEINS CAPABLE OF REVERSIBLE TRANSITION TO A MELT - Provided are compositions and methods for making a variety of products. The methods involve mixing sucker ring teeth (SRT) protein and a plasticizer or a solvent to obtain a mixture of the SRT protein and the plasticizer. When the SRT is mixed with a plasticizer it is heated to between 32° C. and 195° C. to obtain an SRT protein melt. The melt is used to form a wide variety of products. When the SRT is mixed with a solvent, such as an organic solvent or an aqueous solvent, a solution of the SRT protein is formed, and is subsequently used to forming a product from the solution, wherein the product contains SRT protein. | 2016-03-10 |
20160068579 | Trap 63 - The present invention for the first time discloses a novel small molecular weight enamel matrix polypeptide which is at least 80%, such as 90% identical to the amino acid sequence as shown in SEQ ID NO: 1 (MPLPPHPGHP GYINFSYEVL TPLKWYQNMI RHPYTSYGYE PMGGWLHHQI IPWSQQTPQ SHA) (TRAP63), a homologue, analogue, or a pharmaceutically acceptable salt thereof. The present invention further discloses a pharmaceutical composition consisting of an enamel matrix polypeptide which is at least 80%, such as 90% identical to the amino acid sequence as shown in SEQ ID NO: 1, a homologue, analogue, or a pharmaceutically acceptable salt thereof, and a suitable pharmaceutical carrier, which further can consist of one or more enamel matrix polypeptides selected from the group of enamel matrix polypeptides which correspond to: a. SEQ ID NO: 2, b. SEQ ID NO: 3 and c. SEQ ID NO: 4. | 2016-03-10 |
20160068580 | METHOD FOR TREATMENT OF GM1 GANGLIOSIDOSIS - The present invention relates to a method for preparing a GM1 gangliosidosis human cell model based on induced pluripotent stem cells (iPSCs) and iPSCs originated neural progenitor cells, and a use of the GM1 model above for the development of a GM1 gangliosidosis treating agent. The iPSCs originated from GM1 patient fibroblasts can be differentiated into neural progenitor cells (NPCs) and neurosphere cells that can emulate the characteristics shown in GM1 patient, so that the said cells can be efficiently used for the investigation of intracellular GM1 symptoms such as the GM1 gangliosidosis and lysosome accumulation and the gene expression pattern change. So, the GM1 cell model of the present invention can be efficiently used for the study of GM1 development mechanism and the study for the development of a therapeutic agent for the disease. The present inventors also established the inflammasome inhibitor rhIL1RA or Z-YVAD-FMK by using the above GM1 cell model and further confirmed that it can be efficiently used as a relieving/treating agent of GM1 gangliosidosis. | 2016-03-10 |
20160068581 | PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE - The present disclosure is directed to individual Aβ peptide immunogen constructs, peptide compositions comprising these Aβ peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these Aβ peptide immunogen constructs, with the individual Aβ peptide immunogen constructs having the N-terminus of the Aβ peptide as the B cell (B) epitopes linked through spacer residue(s) to heterologous T helper cell (Th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the N-terminus of the Aβ peptide offering protective immune responses to patients at risk for, or with, Alzheimer's Disease. | 2016-03-10 |
20160068582 | CONJUGATE COMPRISING P21 PROTEIN FOR THE TREATMENT OF CANCER - The P21 protein is used as a medicament in the treatment of cancer, conjugate comprises a first region comprising the P21 protein, or a homologue functional fragment thereof; and a second region comprising a translocation factor. | 2016-03-10 |
20160068583 | Interleukin-10 Compositions and Uses Thereof - Interleukin-10 muteins and other interleukin-10-related molecules are described, as well as methods of identifying interleukin-10 muteins and other interleukin-10-related molecules. Also described herein are modifications of the foregoing, which modifications may enhance a property (e.g., half-life) of the muteins or other molecules compared to human interleukin-10. Particular interleukin-10 muteins and related molecules have comparable immunogenicity to human interleukin-10 and/or bioactivity at least comparable to human interleukin-10. Pharmaceutical compositions and methods of use are also described herein. | 2016-03-10 |
20160068584 | CYTOKINE DERIVED TREATMENT WITH REDUCED VASCULAR LEAK SYNDROME - The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an IL-15 derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier. | 2016-03-10 |
20160068585 | COMPOSITIONS AND METHODS FOR TREATMENT OF TYPE 1 DIABETES - The present invention provides compositions and methods for treating insulin-dependent diabetes mellitus in a subject comprising administration of a self-vector encoding and expressing human proinsulin. | 2016-03-10 |
20160068586 | PD-1 ANTIBODIES - A humanised agonistic antibody which binds human PD-1 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:7 for CDR-L3. The invention also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules. | 2016-03-10 |
20160068587 | OLIGOPEPTIDE-FREE CELL CULTURE MEDIA - The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine. | 2016-03-10 |
20160068588 | ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS AND IMMUNOFILTERING - The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo. | 2016-03-10 |
20160068589 | IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES - Anti-SpA murine, chimeric and humanized monoclonal antibodies, and variant antibodies having a heavy chain with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections. | 2016-03-10 |
20160068590 | POLYPEPTIDES AND IMMUNIZING COMPOSITIONS CONTAINING GRAM POSITIVE POLYPEPTIDES AND METHODS OF USE - The present invention provides isolated polypeptides isolatable from a | 2016-03-10 |
20160068591 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND METHODS OF USING THE SAME - Monoclonal antibodies or antigen-binding fragments thereof that bind to | 2016-03-10 |
20160068592 | C5 ANTIBODY AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-RELATED DISEASES - The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation. | 2016-03-10 |
20160068593 | MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER PRDX4 AND USE THEREOF - [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. | 2016-03-10 |
20160068594 | MULTIPLEX IMMUNOASSAYS FOR HEMOGLOBIN, HEMOGLOBIN VARIANTS, AND GLYCATED FORMS - Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided. | 2016-03-10 |
20160068595 | HUMANIZED ANTIBODY AGAINST INTERLEUKIN-20 AND TREATMENT FOR INFLAMMATORY DISEASES - A humanized antibody, or a scFv, Fab, or F(ab′) | 2016-03-10 |
20160068596 | NOTCH PATHWAY INHIBITION - The invention provides Notch pathway inhibition with reduced toxicity. | 2016-03-10 |
20160068597 | FDF03 ANTIBODIES AND USES THEREOF - The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer. | 2016-03-10 |
20160068598 | ANTI-CD19 COMPOSITIONS AND METHODS FOR TREATING CANCER - A composition is provided that includes an anti-CD19 single chain variable fragment (scFv) conjugated to a tumor-associated antigen. The antigen can comprise a Her-2/neu protein, such as a Her-2/neu extracellular domain. Methods of eliciting an immune response are also provided along with methods of treating, or limiting the occurrence of, cancer in a subject. | 2016-03-10 |
20160068599 | METHOD FOR TREATING NEUROENDOCRINE CANCER - Methods for decreasing proliferation and preventing or treating a neuroendocrine cancer using an N-methyl D-aspartate-associated (NMDA) glutamate receptor antagonists or binding agent, such as an antibody, antibody fragment or peptide aptamer specific for a NMDA glutamate receptor, are disclosed. | 2016-03-10 |
20160068600 | ISOLATION OF THERAPEUTIC TARGET SPECIFIC VNAR DOMAINS TO ICOSL - The present invention provides ICOSL specific antigen binding molecules which are isolated from immunized and synthetic Elasmobranchii derived libraries. In particular, the present invention relates to shark Variable New Antigen Receptor (VNAR) domains that specifically bind and neutralize the activity of human Induced Co-Stimulatory Ligand (ICOSL). The neutralizing VNAR domains are isolated from two independent sources; an immunized nurse shark library and a synthetic spiny dogfish framework fusion library. The molecules may be formulated as pharmaceutical compositions and used in medicine. | 2016-03-10 |
20160068601 | TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR - The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain. | 2016-03-10 |
20160068602 | SEQUENCE DEPENDENT AGGREGATION - Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution. | 2016-03-10 |